Bernstein raises Novo Nordisk stock target to DKK620
Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating.
Morgan Stanley sets Novo Nordisk stock at Equalweight
Morgan Stanley (NYSE:MS) initiated coverage on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), a global healthcare company specializing in diabetes care and other serious chronic conditions. The ...
Ozempic shown to reduce drinking in first trial in alcohol-use disorder
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...
Some Ozempic users are developing serious eye issues that lead to vision loss
A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.